menu ☰
menu ˟

Trametinib–dabrafenib combination extended PFS in BRAF-mutated melanoma

29 Sep 2014
The addition of trametinib to dabrafenib significantly prolonged PFS in patients with metastatic melanoma who harbored BRAF V600E or V600K mutations, according to phase 3 study results presented at the European Society of Medical Oncology Annual Cong...

Click here to view the full article which appeared in Dermatology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.